Literature DB >> 30863554

From "high" ZEB1 to "low" B-cell lymphoma 2-interacting mediator of cell death (BIM)-an epithelial-mesenchymal transition (EMT)-associated drug resistance pathway elucidated.

Fabrizio Marcucci1, Cristiano Rumio1.   

Abstract

Entities:  

Year:  2019        PMID： 30863554      PMCID： PMC6384390          DOI： 10.21037/jtd.2018.12.70

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  18 in total

1.  Epithelial-mesenchymal transition: a new target in anticancer drug discovery.

Authors:  Fabrizio Marcucci; Giorgio Stassi; Ruggero De Maria
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

Review 2.  Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads.

Authors:  Fabrizio Marcucci; Matteo Bellone; Carmelo Antonio Caserta; Angelo Corti
Journal:  Int J Cancer       Date:  2013-11-13       Impact factor: 7.396

Review 3.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

4.  Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers.

Authors:  Nancy Dumont; Matthew B Wilson; Yongping G Crawford; Paul A Reynolds; Mahvash Sigaroudinia; Thea D Tlsty
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-19       Impact factor: 11.205

5.  EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.

Authors:  Fumiyuki Sato; Yoshimasa Kubota; Mitsuteru Natsuizaka; Osamu Maehara; Yutaka Hatanaka; Katsuji Marukawa; Katsumi Terashita; Goki Suda; Shunsuke Ohnishi; Yuichi Shimizu; Yoshito Komatsu; Shinya Ohashi; Shingo Kagawa; Hideaki Kinugasa; Kelly A Whelan; Hiroshi Nakagawa; Naoya Sakamoto
Journal:  Cancer Biol Ther       Date:  2015-04-21       Impact factor: 4.742

6.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.

Authors:  Chad J Creighton; Xiaoxian Li; Melissa Landis; J Michael Dixon; Veronique M Neumeister; Ashley Sjolund; David L Rimm; Helen Wong; Angel Rodriguez; Jason I Herschkowitz; Cheng Fan; Xiaomei Zhang; Xiaping He; Anne Pavlick; M Carolina Gutierrez; Lorna Renshaw; Alexey A Larionov; Dana Faratian; Susan G Hilsenbeck; Charles M Perou; Michael T Lewis; Jeffrey M Rosen; Jenny C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-03       Impact factor: 11.205

Review 7.  Oncogenic roles of EMT-inducing transcription factors.

Authors:  Alain Puisieux; Thomas Brabletz; Julie Caramel
Journal:  Nat Cell Biol       Date:  2014-06       Impact factor: 28.824

8.  STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.

Authors:  Seyung S Chung; Nolan Giehl; Yanyuan Wu; Jaydutt V Vadgama
Journal:  Int J Oncol       Date:  2013-11-29       Impact factor: 5.650

9.  Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.

Authors:  Xiaofeng Zheng; Julienne L Carstens; Jiha Kim; Matthew Scheible; Judith Kaye; Hikaru Sugimoto; Chia-Chin Wu; Valerie S LeBleu; Raghu Kalluri
Journal:  Nature       Date:  2015-11-11       Impact factor: 49.962

10.  Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.

Authors:  Kari R Fischer; Anna Durrans; Sharrell Lee; Jianting Sheng; Fuhai Li; Stephen T C Wong; Hyejin Choi; Tina El Rayes; Seongho Ryu; Juliane Troeger; Robert F Schwabe; Linda T Vahdat; Nasser K Altorki; Vivek Mittal; Dingcheng Gao
Journal:  Nature       Date:  2015-11-11       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.